HIV-1 testing: product development strategies.
Strategies for the development of diagnostic products for acquired immune deficiency syndrome (AIDS) are inextricably linked to the status of our knowledge of the human immunodeficiency virus (HIV) and the events associated with the pathogenesis of AIDS. This review traces product development strategies from 1984 to the present day. Product development activities in the HIV-1 antibody screening test market were a response to the need to remove contaminated units from the blood supply. With the successes in screening blood and blood products, there has been a shift towards product development for personal health care and applicant suitability. Identification of markers for disease progression and the need to monitor therapeutic efficacy is now leading to tests for patient disease staging, monitoring and prognosis.
Calypte Biomedical Corporation, Berkeley, CA 94710.
T D
TD
Gottfried
H B
HB
Urnovitz
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis*; D001709:Biotechnology; D001771:Blood Banks; D005544:Forecasting; D015488:HIV Antigens / Q000032:analysis; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007159:Immunologic Tests / Q000379:methods*; D010330:Patents as Topic; D011237:Predictive Value of Tests; D011933:Reagent Kits, Diagnostic
D015488:HIV Antigens; D011933:Reagent Kits, Diagnostic